UNSPSC 51431610: Fendiline hydrochloride

This classification denotes a calcium channel blocker with the molecular formula C23H25N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HEM3Z10IIK, chemically known as n-(3,3-diphenylpropyl)-alpha-methylbenzylamine hydrochloride but more generally known as fendiline hydrochloride, which bears US NIH Compound Identifier 26154. European Medicines Agency schedules Fendiline hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02113MIG.

Most nations, for tariff and trade purposes, schedule fendiline hydrochloride under HS 29214980 and SITC 51454. As of Q4 2014, FENDILINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC(C1CCCCC1)NCCC(C2CCCCC2)C3CCCCC3.CL.

UNSPSC 51431610 Fendiline hydrochloride is a Commodity code covering specific pharmaceutical active ingredients and formulations procured by state and local health agencies for emergency medical services and pharmacy benefit programs. State and local governments buy fendiline hydrochloride and closely related cardiac medications—primarily through emergency services procurement (Tampa Fire Rescue's Advanced Life Support Medications bid) and through state pharmacy benefit programs (Minnesota MMCAP's generic multi-source pharmaceuticals framework and Texas HHS's direct-to-manufacturer prescription initiative). The issuing bodies include municipal fire and rescue departments, state health and human services agencies, and cooperative purchasing alliances serving multiple state and local facilities. Recent solicitations indicate procurement of small-unit quantities (hundreds to low thousands of units annually) with strict expiration-date and shelf-life requirements, delivery timelines measured in days, and compliance obligations including Safety Data Sheets, Good Manufacturing Practices certification, and Drug Supply Chain Security Act attestation.

Recent activity spans Florida, Minnesota, Texas, and Oregon. The City of Tampa's Purchasing Department posted IFB 26P00188 on April 24, 2026 for Advanced Life Support Medications (due April 8, 2026; estimated value $40,000 with a one-year initial term and renewal options), specifying four medication line items including Labetalol, Epinephrine, Adenosine, and Diltiazem with a Small Local Business Enterprise sheltered-market designation and 5 percent SLBE bid discount. The Minnesota Department of Administration's Office of State Procurement issued RFP S1070000015802 through MMCAP on January 20, 2026 (due March 26, 2026) to establish multi-award contracts for generic pharmaceuticals and OTC products across participating state and local facilities, requiring vendor relationships with three authorized wholesalers and emphasizing price competitiveness (75 percent evaluation weight). The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 as a preliminary market-intelligence solicitation regarding direct-to-manufacturer prescription programs, signaling future formal procurement activity. All three opportunities carry insurance, compliance, and quality-assurance requirements typical of state and local pharmaceutical procurement.